Hedge Fund Database
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Oct 26, 2026
The Baird Small/Mid Cap Growth strategy declined -11.47% net of fees (-11.5% as reported in letter commentary) during the third quarter of 2026, underperforming its benchmark, the Russell 2500 Growth Index, which fell -10.35%. Year-to-date, the strategy declined -0.72% net of fees versus a +7.28% return for the benchmark. In contrast to large-cap equities, where the S&P 500 rose approximately 2% led by mega-cap technology and AI beneficiaries, small- and mid-cap equities faced significant headwinds. Although the strategy's broader factor backdrop proved favorable, results were hindered by stock-specific weakness heavily concentrated in the industrials and consumer discretionary sectors. Macroeconomic conditions grew increasingly complex as higher interest rates, elevated oil prices, and the Federal Reserve's first rate hike in three years raised acute concerns regarding persistent inflation and the sustainability of economic expansion. Market leadership narrowed considerably, and market factor patterns experienced sharp reversals from month to month. Within the portfolio, healthcare was the strongest relative contributor behind life sciences tools and AI-driven tailwinds, while industrial holdings and restaurant-heavy discretionary positions faced sharp pressure from cost inflation and shifting consumer sentiment. Portfolio management actively adjusted exposures across key sectors. The team established new positions in software providers Guidewire and Tyler Technologies to capture multi-year expansion with minimal AI displacement risk, and initiated a position in Brown-Forman citing asymmetric upside potential. Conversely, the strategy completely divested positions in Boot Barn, Waystar, Houlihan Lokey, Alignment Healthcare, and Jabil due to growth downgrades, quality concerns, or cyclical de-risking, while harvesting gains by trimming Twist Bioscience following a 90% rally.
Invest in small- and medium-sized, high-quality growth companies holding leadership positions within their industries that are capable of producing above-average growth across varied market environments.
Economic activity and consumer fundamentals remain favorable, though higher interest rates, energy prices, fiscal risks, and election uncertainties reinforce the need for portfolio balance and valuation discipline as stock prices diverge from business values.
Moderate Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Baird Small/Mid Cap Growth Equity Fund or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.